Berlin Declaration: Biopharmaceutical Industry Vision for Equitable Access in Pandemics
The innovative biopharmaceutical industry, having developed COVID-19 vaccines and treatments at record speed and in historic quantities, proposes to create a collaborative solution for more equitable rollout of vaccines, treatments and diagnostics for future pandemics.
In particular, the innovative biopharmaceutical industry is willing to reserve an allocation of real-time production of vaccines, treatments and diagnostics for priority populations in lower income countries and take measures to make them available and affordable.
We call on other stakeholders to work together with industry to shape a future where everyone is better protected from the threat of pandemics. Tweet this
To be successful, we call on other stakeholders to work together with industry to help make this proposal a reality and shape a future where everyone is better protected from the threat of pandemics.
This Berlin Declaration draws on the lessons we have learned and sets out an approach for more equitable pandemic preparedness and response, based on commitments and contributions from a global collaboration of public, private and charitable sectors together with civil society. Critical for success is to ensure that pandemic VTDs reach those who need them most, no matter where they live, from the outset of future pandemics.
About IFPMA
IFPMA represents the innovative pharmaceutical industry at the international level, engaging in official relations with the United Nations and multilateral organizations. Our vision is to ensure that scientific progress translates into the next generation of medicines and vaccines that deliver a healthier future for people everywhere.
ifpma.org
To achieve this, we act as a trusted partner, bringing our members' expertise to champion pharmaceutical innovation, drive policy that supports the research, development, and delivery of health technologies, and create sustainable solutions that advance global health.
